Etanercept in the treatment of rheumatoid arthritis

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules

(2012) Ryoko Sakai et al.   ANNALS OF THE RHEUMATIC DISEASES

Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and

(2012) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register

(2012) James B Galloway et al.   ANNALS OF THE RHEUMATIC DISEASES

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register

(2012) Louise K Mercer et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

(2012) Charlotte L. Krieckaert et al.   ARTHRITIS AND RHEUMATISM

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

(2012) Larry W. Moreland et al.   ARTHRITIS AND RHEUMATISM

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

Longterm Retention of Tumor Necrosis Factor-  Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

(2012) F. IANNONE et al.   JOURNAL OF RHEUMATOLOGY

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

(2011) X. Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE

(2011) Robert Löfberg et al.   INFLAMMATORY BOWEL DISEASES

The Growth Factor Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory Arthritis in Mice

(2011) W. Tang et al.   SCIENCE

New horizons in natural TNF-α antagonist research

(2011) Jagadeesh Bayry   TRENDS IN MOLECULAR MEDICINE

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study

(2010) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

(2010) Peter C Taylor   CURRENT OPINION IN PHARMACOLOGY

Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis Ankylosing Spondylitis

(2010) Simon Y. Zhou et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Path to Personalized Medicine

(2010) Margaret A. Hamburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

(2010) T. Ding et al.   RHEUMATOLOGY

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Systematic review and meta-analysis: Anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis

(2010) Cheryl Barnabe et al.   ARTHRITIS CARE & RESEARCH

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial

(2009) J Kekow et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

(2009) Sophie Martin Du Pan et al.   ARTHRITIS AND RHEUMATISM

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

(2009) F. Tubach et al.   ARTHRITIS AND RHEUMATISM

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

(2009) Merete Lund Hetland et al.   ARTHRITIS AND RHEUMATISM

Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid Arthritis

(2009) Jay R. McDonald et al.   CLINICAL INFECTIOUS DISEASES

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

(2009) Anja Strangfeld   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy

(2008) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

(2008) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

(2008) J Askling et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double‐blind, active drug–controlled study

(2008) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports

(2008) Primal P. Kaur et al.   CLINICAL RHEUMATOLOGY

Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial

(2008) M. A. Judson et al.   EUROPEAN RESPIRATORY JOURNAL

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET